DOI 10.1016/j.jchf.2025.102751
Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced.
Аннотация
BACKGROUND
Magnesium plays a central role in maintaining cellular homeostasis. Limited data exist on the clinical implications of magnesium derangements in heart failure with reduced ejection fraction (HFrEF) and on the influence of sodium-glucose cotransporter 2 (SGLT2) inhibitors on serum magnesium levels.
OBJECTIVES
Using the EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction; NCT03057977) population, the authors studied the association of serum magnesium with outcomes, assessed the impact of empagliflozin on serum magnesium levels, and explored the influence of serum magnesium on the effect of empagliflozin on cardiovascular and renal outcomes.
METHODS
Patients with HFrEF were randomized to receive placebo or 10 mg/day of empagliflozin. Laboratory results were available at baseline, week 4, weeks 12, 32, and 52, and every 24 weeks thereafter. The median follow-up time was 16 months. The primary outcome was a composite of cardiovascular death or heart failure (HF) hospitalization.
RESULTS
A total of 3,730 patients were included. The mean serum magnesium levels at baseline were 0.83 ± 0.11 mmol/L. The corresponding magnesium quintiles were Q1 = 0.68 ± 0.07 mmol/L (n = 878); Q2 = 0.79 ± 0.02 (n = 724); Q3 = 0.84 ± 0.01 (n = 668); Q4 = 0.88 ± 0.02 (n = 733); and Q5 = 0.97 ± 0.05 (n = 727). The patients with higher magnesium levels were older and had a lower estimated glomerular filtration rate. Conversely, the patients with lower serum magnesium had diabetes more frequently. Lower magnesium levels were modestly associated with a higher risk of HF and kidney events; such associations were attenuated with full covariate adjustment. The effect of empagliflozin (vs placebo) on the study primary outcome was more pronounced at lower baseline serum magnesium levels (Q1 HR: 0.54 mmol/L [95% CI: 0.41-0.71 mmol/L]; Q2 HR: 0.69 mmol/L [95% CI: 0.50-0.96 mmol/L]; Q3 HR: 0.82 mmol/L [95% CI: 0.58-1.15 mmol/L]; Q4 HR: 0.99 mmol/L [95% CI: 0.72-1.37 mmol/L]; and Q5 HR: 0.87 mmol/L [95% CI: 0.65-1.17 mmol/L], Pinteraction = 0.043). Empagliflozin rapidly increased magnesium levels by 0.05 mmol/L. The relative odds of experiencing lower magnesium levels were reduced with empagliflozin.
CONCLUSIONS
In EMPEROR-Reduced, low serum magnesium levels were modestly associated with poor HF and kidney outcomes. Empagliflozin increased serum magnesium levels and was associated with a more pronounced reduction of HF events among patients with low magnesium levels at baseline.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.